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Abstract 
The Global Initiative for Asthma (GINA) Strategy Report provides clinicians with an 
annually updated evidence-based strategy for asthma management and prevention, which can 
be adapted for local circumstances (e.g., medication availability). This article summarizes key 
recommendations from GINA 2021, and the evidence underpinning recent changes. 
GINA recommends that asthma in adults and adolescents should not be treated solely with 
short-acting beta2-agonist (SABA), because of the risks of SABA-only treatment and SABA 
overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials show that as-
needed combination ICS-formoterol reduces severe exacerbations by ≥60% in mild asthma 
compared with SABA alone, with similar exacerbation, symptom, lung function and 
inflammatory outcomes as daily ICS plus as-needed SABA. 
Key changes in GINA 2021 include division of the treatment figure for adults and adolescents 
into two tracks. Track 1 (preferred) has low-dose ICS-formoterol as the reliever at all steps: 
as-needed only in Steps 1-2 (mild asthma), and with daily maintenance ICS-formoterol 
(maintenance-and-reliever therapy, MART) in Steps 3-5. Track 2 (alternative) has as-needed 
SABA across all steps, plus regular ICS (Step 2) or ICS-long-acting beta2-agonist (LABA) 
(Steps 3-5). For adults with moderate-to-severe asthma, GINA makes additional 
recommendations in Step 5 for add-on long-acting muscarinic antagonists and azithromycin, 
with add-on biologic therapies for severe asthma. For children 6-11 years, new treatment 
options are added at Steps 3-4.  
Across all age-groups and levels of severity, regular personalized assessment, treatment of 
modifiable risk factors, self-management education, skills training, appropriate medication 
adjustment and review remain essential to optimize asthma outcomes. 
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Introduction 
Asthma is a serious global health problem affecting all age groups.1 Its prevalence has 
increased in many countries, especially among children. The Global Initiative for Asthma 
(GINA) aims to improve the diagnosis, management and prevention of asthma by providing 
an up-to-date evidence-based strategy and tools and practical resources for clinicians 
worldwide.  
GINA was established through a 1993 collaboration between the World Health Organization 
(WHO) and the US National Heart, Lung, and Blood Institute to develop a strategy for the 
diagnosis and management of asthma.2 The Global Strategy for Asthma Management and 
Prevention (GINA strategy report) has been updated annually since 2002, to provide 
clinicians with up-to-date evidence-based recommendations as new evidence emerges and 
new therapies are approved. The GINA strategy report is under continual review by the 
Science Committee. GINA methodology3 involves evaluation of new evidence identified 
from a twice-yearly rolling review of original research and systematic reviews (not limited to 
specific PICO [population/intervention/comparison/outcomes] questions), assessment of its 
impact on existing or new recommendations, and consideration of whether and how it should 
be integrated into the overall asthma management strategy. GINA is independent of industry. 
This article summarizes key recommendations from the 2021 GINA strategy report,4 
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Key recommendations [text box] 
1. Diagnosis: In adults, adolescents and children ≥6 years, confirm the diagnosis of asthma 
before starting controller treatment, whenever possible, as it is often more difficult afterwards. 
In children ≤5 years, recurrent wheezing is common, but asthma is more likely if they have 
wheezing or coughing with exercise/laughing/crying or in the absence of respiratory 
infections, and if they have a history of eczema or allergic rhinitis. 
2. Personalized assess-treat-review cycles: Asthma management should be personalized and 
adjusted in a continual cycle of assessment, treatment and review, to minimize symptoms and 
prevent exacerbations. Consider symptom control, risk factors for exacerbations and side-
effects, lung function, comorbidities, self-management skills, and patient and/or caregiver 
goals, preferences and satisfaction. 
3. Comprehensive care: Asthma management is not ‘one-size-fits-all’. It includes not only 
medication, but also treatment of modifiable risk factors and comorbidities, non-
pharmacological strategies, and education and skills training, particularly for inhaler 
technique and adherence. 
4. Inhaled corticosteroids (ICS): Asthma in adults and adolescents should not be managed 
solely with short-acting beta2-agonists (SABA). Instead, to reduce the risk of severe 
exacerbations, and to control symptoms, all adults and adolescents with asthma should be 
treated with ICS-containing therapy: either regularly every day or, in mild asthma, with ICS-
formoterol taken as needed for symptom relief. ICS-containing treatment is also 
recommended for all children 6-11 years with asthma: either regularly or, in mild asthma, by 
taking ICS whenever SABA is taken. The past distinction between ‘intermittent’ and ‘mild 
persistent’ asthma was arbitrary and does not predict differential response to ICS. 
Page 5 of 75
 AJRCCM Articles in Press. Published as 10.1164/rccm.202109-2205PP 
 Copyright © by the American Thoracic Society 
GINA 2021 Executive summary  
4 
5. Treatment tracks: In 2021, for clarity, GINA treatment for adults and adolescents was 
divided into two tracks, depending on the inhaled reliever medication. Across the five steps, 
treatment may be stepped up or down within a track, using the same reliever at each step, or 
switched between tracks, according to the patient’s needs and preferences: 
• Track 1, with low-dose ICS-formoterol as the reliever. This is the overall preferred 
approach because it reduces the risk of severe exacerbations, compared with using a 
SABA reliever (with/without maintenance controller), with similar symptom control, 
similar lung function, and lower oral corticosteroid (OCS) burden. In Steps 1-2, there are 
additional reasons for preferring as-needed-only ICS-formoterol over as-needed SABA 
(alone or with daily ICS): (i) Patients with ‘mild’ asthma can have severe exacerbations, 
(ii) adherence with daily ICS is almost universally poor in patients with mild or infrequent 
symptoms, leaving them at higher risk of severe exacerbations, and (iii) starting treatment 
with SABA alone trains patients to regard it as their main asthma treatment. As-needed-
only ICS-formoterol (without maintenance treatment) in Steps 1-2 should be distinguished 
from Maintenance And Reliever Therapy (MART)* in Steps 3-5, where patients also take 
ICS-formoterol as daily maintenance treatment. MART is also an option for children 6-11 
years in Steps 3-4. ICS-formoterol should not be used as reliever for patients taking a 
combination non-formoterol ICS-long-acting beta2 agonist (LABA), with/without long-
acting muscarinic antagonist (LAMA). 
• Track 2, with SABA as the reliever. This is an alternative approach (e.g., if Track 1 is 
not possible, or is not preferred by a patient with no exacerbations in the last year). 
However, before considering a regimen with SABA reliever, consider whether the patient 
is likely to adhere to controller therapy. If not, they will be exposed to the risks of SABA-
only treatment. For Step 1, taking ICS whenever SABA is taken is preferable to SABA 
alone. 
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For either track, GINA provides an integrated approach and decision tree for difficult-to-treat 
and severe asthma, with add-on therapies in Step 5 for severe asthma including biologic 
therapy guided by inflammatory phenotype. 
6. Children ≤5 years: Manage wheezing episodes initially with inhaled SABA. Consider 
trialing controller therapy (e.g., for 3 months) if the symptom pattern suggests asthma, 
alternative diagnoses have been excluded, and respiratory symptoms and/or wheezing 
episodes are frequent or severe. 
7. Stepping up: Before stepping up treatment to control symptoms or prevent exacerbations, 
confirm that the symptoms are due to asthma, and identify and address modifiable risk factors 
including incorrect inhaler technique, poor medication adherence, environmental exposures 
and multimorbidity, and provide patient education. 
8. Stepping down: Once asthma is well controlled for 2-3 months, consider stepping down 
gradually to find the minimum effective dose, monitoring the patient frequently. Step up 
again if needed. 
9. Asthma action plans: As part of supported asthma self-management, provide a 
personalized written asthma action plan for all patients, tailored to their health literacy, so 
they know how to recognize and respond to worsening asthma. 
10. Referral: Refer patients for expert advice if any of the following apply: 
• The diagnosis of asthma cannot confidently be confirmed. For children ≤5 years, strongly 
consider referral for further diagnostic investigations if there is very early onset of 
symptoms, failure to respond to treatment, or features suggesting alternative diagnoses 
(e.g., hypoxemia, finger clubbing, failure to thrive). 
• Occupational asthma is suspected. 
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• The patient has any risk factors for asthma-related death. 
• Symptoms or exacerbations remain uncontrolled despite medium/high-dose ICS-LABA. 
• The patient needs urgent health care or OCS more than once a year. 
• There is evidence or high risk of treatment side-effects. 
• Food allergy is suspected. 
*also called single-inhaler maintenance-and-reliever therapy (SMART)  
 
 
Asthma management during the COVID-19 pandemic  
Patients with asthma are not at increased risk of acquiring COVID-19, or of severe 
COVID-19. Advise patients to continue taking their prescribed asthma medicines, including 
ICS, alone or in combination with a LABA, and biological therapy for severe asthma. 
Avoid the use of nebulizers, where possible, due to the risk of viral transmission. Within 
healthcare facilities, follow local infection control procedures and COVID-19 testing 
recommendations if spirometry, peak expiratory flow (PEF) measurement, or other aerosol-
generating procedures (e.g., oxygen therapy, sputum induction, ventilation) are needed. 
GINA recommends COVID-19 vaccination for people with asthma, with usual precautions 
including checking for allergy to vaccine ingredients. Anaphylaxis to foods, insect venom or 
medications is not a contraindication. Consider giving biological therapies on a different day 
from COVID-19 vaccine. 
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Definition, description and diagnosis of asthma 
Asthma is a heterogeneous disease defined by the history of respiratory symptoms 
(e.g., wheeze, shortness of breath, chest tightness and cough) that vary over time and in 
intensity, together with variable expiratory airflow limitation. Airflow limitation may later 
become persistent. 
Asthma is usually associated with airway hyperresponsiveness and airway inflammation, but 
these are not necessary or sufficient for diagnosis. Clinical phenotypes (e.g., childhood-onset 
versus late-onset, allergic versus nonallergic) do not correlate strongly with specific 
pathological processes or treatment responses. 
The diagnosis of asthma is based on a history of characteristic symptom patterns and evidence 
of variable expiratory airflow limitation from bronchodilator reversibility testing or from 
other tests such as positive bronchial provocation test, excessive variability on PEF 
monitoring, excessive variation in forced expiratory volume in 1 second (FEV1) between 
visits, or a significant increase in FEV1 after ICS treatment (Table E1 in online data 
supplement). Explain to patients that often, more than one of these tests is needed5. Evidence 
for the diagnosis of asthma should be confirmed before starting controller treatment, if 
possible, to avoid inappropriate treatment or missing other important diagnoses, and because 
diagnosis is often more difficult later. Clinical examination, including chest auscultation, may 
be completely normal. 
Fractional concentration of exhaled nitric oxide (FeNO) is higher in asthma with Type 2 
airway inflammation, but also in atopy, allergic rhinitis, eczema and eosinophilic bronchitis, 
and it is lower during bronchoconstriction and in some asthma phenotypes (e.g., neutrophilic 
asthma). It can be increased or decreased by viral respiratory infections. 
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Additional strategies may be needed to confirm the diagnosis of asthma in particular 
populations, including patients already on controller treatment (GINA 2021, Box 1-3), the 
elderly, smokers, and those in low-resource settings. The differential diagnosis of asthma 
varies by age (GINA 2021, Box 1-5). 
 
Assessment of asthma 
Asthma control is defined as the extent to which the features of asthma are apparent or have 
been reduced or eliminated by controller treatment6. Assess asthma control within two 
domains: symptom control, and risk of adverse outcomes, particularly exacerbations. 
Symptom control 
Assess symptom control from asthma-related symptom frequency, night-waking and activity 
limitation, and, for patients using SABA reliever, frequency of SABA use (Figure 1). Other 
symptom control tools include Asthma Control Test7 and Asthma Control Questionnaire 
(preferably the 5-item version, i.e. ACQ-5).8 
Rationale: Historically, frequency of SABA reliever use (<2 or ≥2 days/week) was included 
in the composite assessment of symptom control. This distinction was arbitrary, based on the 
assumption that if SABA was used on >2 days in a week, the patient needed to start controller 
therapy or increase the dose. However, if a patient uses as-needed ICS-formoterol as their 
reliever on average >2 days/week, this is already providing additional controller therapy, so 
further dose escalation may not be needed. Therefore, use of ICS-formoterol reliever ≤2 
versus >2 days/week is not included in the composite assessment of symptom control. 
Instead, average frequency of ICS-formoterol use over the past 4 weeks should be assessed 
separately when the patient’s maintenance controller dose is reviewed. 
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Risk factors 
Assess every patient’s risk of exacerbations, even when symptom control is good. Although 
patients with poor symptom control are more likely to have exacerbations, patients with few 
or no symptoms can still have severe or even fatal exacerbations, including with external 
triggers such as viral respiratory infections.9 Factors that increase a patient’s risk of 
exacerbations even if they have few symptoms include ≥1 exacerbation in the previous year, 
over-use of SABA (e.g., ≥3 x 200-dose albuterol [salbutamol] canisters/year, i.e., average 
more than daily use), inadequate ICS use (under-treatment, poor adherence, incorrect inhaler 
technique), some comorbidities (including obesity, chronic rhinosinusitis, gastroesophageal 
reflux, confirmed food allergy), low FEV1, high blood eosinophil count in patients with 
Type 2 inflammation, and major psychological or socioeconomic problems. Also assess risk 
factors for persistent airflow limitation and medication side-effects (Figure 1). 
Lung function testing 
Record lung function at diagnosis, 3-6 months after starting treatment, and then periodically 
(e.g., at least once every 1-2 years; more often in at-risk patients and those with severe 
asthma), to identify progressive decline. Lung function at individual visits is of limited use for 
guiding treatment because of its large (up to 20%) visit-to-visit variation.10 Investigate further 
if there are few symptoms but impaired lung function, which may indicate poor perception11 
or long-term adaptation; or frequent symptoms despite good lung function, which may 
indicate an alternative cause for the symptoms (GINA 2021, Box 1-5). 
Asthma severity 
By consensus6, asthma severity is assessed retrospectively, after at least 2-3 months of 
treatment, from the level of treatment required to control symptoms and exacerbations. GINA 
does not distinguish between so-called ‘intermittent’ and ‘mild persistent’ asthma because this 
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historical distinction was arbitrary, with no evidence of a difference in treatment response. 
Severe asthma is asthma that remains uncontrolled despite optimized treatment with high-
dose ICS-LABA, or that requires such treatment to prevent it becoming uncontrolled.12 It is 
important to distinguish between severe asthma and difficult-to-treat asthma, i.e., asthma that 
is uncontrolled due to other factors, such as incorrect inhaler technique, poor adherence, and 
comorbidities such as obesity, and environmental exposures.13 
Rationale: This definition of asthma severity works well at the severe end of the spectrum but 
is less useful for describing mild asthma (see Topics requiring further research). For 
example, patients with infrequent or no interval symptoms can still have severe exacerbations. 
This risk is reduced to a similar extent by either daily ICS treatment14, 15 or by ICS-formoterol 
taken only for symptom relief,15 and baseline symptom frequency does not predict need for 
daily ICS.15, 16 
 
General principles of asthma management 
The goals of asthma management are to achieve good symptom control, relieve symptoms 
when they occur, and minimize risk of exacerbations and asthma-related death, persistent 
airflow limitation and side-effects of treatment. The patient’s own treatment goals should be 
identified because they may be different. Effective asthma management requires a partnership 
between the patient (or parent/caregiver) and healthcare providers, with shared decision-
making and good communication.  
Asthma management is not ‘one-size-fits-all’, but instead should be personalized and adjusted 
in a continual cycle of assessment, treatment adjustment, and review (Figure 2). 
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Assessment 
Assess not only symptom control and lung function, but also the individual’s modifiable risk 
factors and comorbidities (also called ‘treatable traits’),17 and patient/parent goals and 
preferences. Check adherence and inhaler technique frequently. Poor symptom control is 
associated with much higher risk of exacerbations, but patients with apparently mild asthma 
or with good symptom control can still have severe or life-threatening exacerbations.9, 14, 18 
Treatment adjustment 
Treatment adjustment includes not only changes in asthma medication dose or type, but also 
multidisciplinary management of modifiable risk factors and comorbidities (GINA 2021, 
Section 3D), and non-pharmacological strategies such as smoking cessation and avoidance of 
indoor/outdoor air pollution (GINA 2021, Box 3-9). 
For all patients, provide regular training in inhaler technique and asthma self-management, 
including self-monitoring of symptoms and/or PEF, and a written asthma action plan19 (GINA 
2021, Section 3C). Encourage adherence with controller medication, even when symptoms 
are infrequent. Consider stepping down treatment when good control has been maintained for 
2-3 months (GINA 2021, Box 3-7). 
Review 
Arrange regular medical review to identify modifiable risk factors, optimize care and 
minimize the risk of exacerbations: review at least yearly (more often in patients with 
moderate or severe asthma), after an exacerbation, and after a treatment change. Review 
clinical outcomes and side effects, patient/parent/caregiver satisfaction, inhaler technique and 
self-management skills. Ensure the patient/caregiver has an up-to-date written asthma action 
plan. 
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Rationale: The GINA strategy (Figure 2) considers not only patient characteristics that may 
predict a clinically important difference in treatment response, but also medication access, the 
patient’s preferences, and practical issues of cost, ability to use the inhaler, and likely 
adherence. The extent to which asthma treatment can be individualized according to patient 
characteristics or phenotype depends on the health system, the clinical context, evidence 
about the magnitude of potential difference in outcomes, cost, and available resources. 
 
Medications and strategies for symptom control and risk reduction 
Asthma medications are categorized as controllers, relievers, and add-on therapies: 
• Controllers contain ICS, which reduce airway inflammation, control symptoms, and 
reduce the risks of exacerbations20, even in mild asthma,14, 15, 21 and of asthma death.22 
Treatment with ICS may reduce exacerbation-related decline in lung function.23 
‘Maintenance’ therapies are controllers that are prescribed for daily use. 
• Relievers (low-dose ICS-formoterol or SABA) contain rapid-onset bronchodilators. 
They are used ‘as needed’, i.e., for quick relief of symptoms, including during 
exacerbations. Using ICS-formoterol as reliever (often called an ‘anti-inflammatory 
reliever’ or AIR) also reduces the risk of severe exacerbations, compared with SABA 
reliever, both with24, 25 or without15, 21 maintenance controller treatment. SABA or 
ICS-formoterol is also recommended before exercise if needed to prevent exercise-
induced bronchoconstriction.26, 27 
• Add-on therapies are mainly for patients with difficult-to-treat or severe asthma (see 
below). 
When choosing medications, consider local guidelines, regulatory approvals and payer 
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criteria. 
Recommendation against SABA-only treatment 
Since 2019, GINA has recommended against SABA-only treatment of asthma in adults and 
adolescents, after consideration of its risks and the evidence for a safer alternative.28 Instead, 
to reduce the risk of serious exacerbations and control symptoms, all adults and adolescents 
with asthma should receive ICS-containing treatment, either regularly or, in mild asthma, 
symptom-driven28. ICS is now also recommended for all children 6-11 years with asthma, 
either regularly or, in mild asthma, whenever SABA is taken for symptom relief. 
Rationale: Although SABA is inexpensive and relieves symptoms quickly, treatment of 
asthma with SABA alone is associated with increased risk of asthma-related death22 and of 
urgent asthma-related healthcare,20 even in patients with so-called ‘intermittent’ asthma.29 
Overuse of SABAs (≥3 x 200-dose albuterol canisters/year) is associated with incrementally 
increasing risk of asthma exacerbations and mortality, including in patients treated with 
SABA alone.22 Regular use of SABA, even 2-4 times/day for 1-2 weeks, is associated with 
beta2 receptor downregulation, loss of bronchodilator response, increased airway 
hyperresponsiveness, and increased airway inflammation.30, 31 Importantly, from a cognitive 
and behavioral perspective, starting treatment with SABA alone trains the patient to regard it 
as their main asthma treatment, increasing the challenges for adherence with any subsequent 
advice to take ICS every day even when asymptomatic. 
By contrast, in mild asthma, as-needed ICS-formoterol decreases the risk of severe 
exacerbations requiring OCS by ≥60% compared with SABA alone,15, 21 including in patients 
without elevated Type 2 inflammatory markers,15, 32 with a very small average daily ICS 
dose.15, 16, 21, 33 Starting treatment with as-needed ICS-formoterol in patients with mild asthma 
addresses both symptom relief and risk reduction, without the need for daily maintenance 
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treatment. 
GINA treatment tracks for adults and adolescents 
There are five levels of treatment (Steps 1-5; Figure 3), with two ‘tracks’, depending on the 
choice of reliever: ICS-formoterol (Track 1, preferred) or SABA (Track 2, alternative). 
Treatment may be stepped up or down within a track using the same reliever at each step, or 
switched between tracks. 
Within Track 1, the reliever is as-needed low-dose ICS-formoterol. This means that when a 
patient at any treatment step has asthma symptoms, they take low-dose ICS-formoterol for 
symptom relief. In Steps 1-2, this also provides the patient’s controller therapy and reduces 
severe exacerbation risk,15, 16, 21, 33 without daily maintenance treatment. This is distinguished 
from Maintenance-And-Reliever Therapy (MART) in Steps 3-5, where patients take ICS-
formoterol both as daily maintenance treatment and, as needed, for symptom relief (Table 1). 
Track 2, with SABA reliever, is suggested where ICS-formoterol is not available, or is not 
preferred by a patient at low risk of exacerbations (including having no exacerbations in the 
past year). Before prescribing therapy with SABA reliever, consider if the patient is likely to 
be poorly adherent with ICS controller therapy, as this increases the risk of exacerbations.  
In Figure 3, additional or alternative treatments with less evidence for safety, efficacy and/or 
effectiveness are shown as ‘other controller options’. 
Rationale: GINA introduced two tracks into the 2021 treatment figure for adults and 
adolescents (Figure 3) to clarify: 
• how to step treatment up or down within the different reliever options (ICS-formoterol 
or SABA) 
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• that SABA is the recommended reliever for patients prescribed maintenance non-
formoterol ICS-LABA. 
The Track 1 approach is preferred overall because it reduces the risk of severe exacerbations 
compared with using a SABA reliever, with similar symptom control and lung function, and it 
integrates messaging about the importance of both symptom control and risk reduction across 
all treatment steps, including Step 1. The figure also summarizes the main considerations for 
choosing ICS-formoterol or SABA as reliever, and reinforces the key elements of 
personalized asthma treatment. 
GINA treatment steps for adults and adolescents (Figure 3) 
Steps 1 and 2 preferred treatment (Track 1): The preferred treatment for adults and 
adolescents with mild asthma is low-dose ICS-formoterol taken as needed for symptom relief, 
without maintenance treatment. As-needed-only ICS-formoterol is usually prescribed as 
budesonide-formoterol 200/6 mcg metered dose (160/4.5 mcg delivered dose) 1 inhalation as 
needed (Table 1; for dosage details see Table E2 and downloadable resource). Other 
combination ICS-formoterol products may be suitable but have not yet been studied. 
Rationale: Considerations for the recommendations at Steps 1 and 2 are interrelated. In 
patients eligible for Step 2 treatment, two large studies found that as-needed ICS-formoterol 
reduced the risk of severe exacerbations by almost two-thirds compared with SABA-only 
treatment.15, 21 Four studies (~10,000 patients) showed a similar or greater reduction in severe 
exacerbations compared with daily low-dose ICS, without clinically important differences in 
symptom control,15, 16, 21, 33 lung function,15, 16, 21, 33 or airway inflammation measured by 
FeNO15, 16 over 12 months. The primary outcome variable of one study21 was ‘well-controlled 
asthma weeks’, but this outcome was not considered reliable because it was based on a past 
definition of asthma control, and was systematically biased against the as-needed ICS-
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formoterol treatment group in which patients were permitted much less ICS than those on 
maintenance ICS before a week was classified as not well-controlled. In two studies that 
showed greater overall reduction in risk of severe exacerbations reduction with as-needed 
ICS-formoterol compared with maintenance ICS plus as-needed SABA,15, 16 no predictors of 
differential response were identified among many baseline characteristics, including 
inflammatory phenotype,15, 16 except for a clinically unimportant difference in ACQ-5 in one 
study.16 
In Step 1, the recommendation for as-needed low-dose ICS-formoterol for adults and 
adolescents with symptoms less than twice/month is supported by indirect evidence for a 
large reduction in risk of severe exacerbations, compared with as-needed SABA alone.15, 21 
Extension of this recommendation to Step 1 was also supported by several important 
considerations: 
• Historically, recommendations for as-needed SABA alone were never supported by 
evidence of long-term safety or efficacy; early guidelines had assumed that patients 
with mild asthma would not benefit from ICS, and were concerned about its risks 
based on experience with OCS. 
• The past distinction between eligibility for Step 1 and Step 2 treatment based on 
symptom frequency (e.g., ≤ or >2 days/week) was arbitrary, not evidence-based. 
• The use of as-needed ICS-formoterol markedly reduces severe exacerbations, 
compared with as-needed SABA, even in patients with SABA use ≤2/week at baseline 
(so-called ‘intermittent’ asthma)15. 
• A single day with >2, >4, >6 or >8 doses of as-needed budesonide-formoterol reduced 
the short-term (21-day) risk of severe exacerbations, compared with as-needed SABA 
alone (post hoc analysis).34 A similar effect was seen with ICS-formoterol MART in 
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Steps 3-4.35, 36 
• Even modest over-use of SABA (e.g., dispensing ≥3 albuterol canisters/year, 
i.e., average ≥1.6 puffs/day) is associated with increased risk of severe exacerbations37 
and, in one study, higher asthma mortality.38 
• Even occasional short courses of OCS (e.g., 4-5 courses over 7 years, 
i.e., <1 course/year), are associated with significant short-term risks39 and cumulative 
risks of long-term adverse effects such as osteoporosis and diabetes.40 
• Regular daily low-dose ICS treatment is highly effective in reducing asthma 
symptoms and risk, including in patients with infrequent symptoms, but poor 
adherence to ICS is common41, exposing patients to the risks of SABA-only treatment. 
• As-needed budesonide-formoterol is well tolerated in mild asthma.15, 16, 21, 33 
• Starting treatment with SABA alone trains the patient to regard it as their primary 
asthma treatment. 
Steps 1 & 2 alternative treatment (track 2): The Step 2 recommendation for adults and 
adolescents remains regular low-dose ICS with as-needed SABA. The Step 1 
recommendation is taking ICS whenever SABA is taken (combination or separate inhalers). 
Rationale: For patients with initial symptoms twice/month or more, low-dose maintenance 
ICS reduces the risk of serious exacerbations by almost half compared with SABA alone.14 
There is a paucity of evidence for safety and effectiveness of as-needed concomitant 
ICS+SABA, as only small groups received this regimen in studies of adults42, 43 and children 
5-18 years.44, 45 However, it would be preferable to SABA alone if ICS-formoterol is not 
available or affordable. No data are available about the acceptability to adults of carrying 
separate ICS and SABA inhalers for symptom relief, or what proportion of patients revert to 
SABA-only use. No data are available about safe levels of as-needed ICS+SABA use, but in 
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one study, exacerbations were higher among patients randomized to twice-daily ICS-SABA 
than those on as-needed ICS-SABA,42 consistent with risks associated with SABA overuse.38 
Steps 3 and 4: The preferred Step 3 treatment is maintenance and reliever therapy with low-
dose ICS-formoterol (MART),24, 25, 46 which is approved in many countries with budesonide-
formoterol and beclometasone-formoterol. For Step 4, if needed, the maintenance dose of 
ICS-formoterol can be increased to medium.36, 47, 48 The doses of ICS-formoterol 
recommended for MART, including the maximum dose in any day, are shown in Table E2 
and the downloadable resource. 
Rationale: In adults and adolescents with poor symptom control and ≥1 exacerbation in the 
previous year, MART reduced exacerbations and provided similar symptom control at 
relatively low ICS doses, compared with maintenance ICS-LABA or higher-dose ICS, both 
with as-needed SABA.24, 49-51 In open-label studies in broader populations, MART also 
significantly reduced severe exacerbations, with a lower average dose of ICS.25, 46 ICS-
formoterol should not be used as the reliever for patients taking maintenance non-formoterol 
ICS-LABA, because there are no data for efficacy and safety. 
Step 5: See Difficult-to-treat and severe asthma, below. 
Choosing initial asthma treatment: when choosing the track and starting step for initial 
treatment (GINA 2021, Boxes 3-4A-D), consider not only the patient’s current symptoms and 
risk of exacerbations, but also practical issues including medication access (availability and 
cost), inhaler technique, likely adherence, and patient preferences. Before starting, record 
evidence for the diagnosis of asthma, the patient’s symptom control and risk factors, 
including lung function, and check that they can use the inhaler correctly. Provide education 
and skills training, and schedule a follow-up visit to assess response (Figure 2).  
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During ongoing treatment, medication may be adjusted up or down within the same track 
(i.e., with the same reliever) or may be switched between tracks, depending on patient needs. 
However, for patients prescribed as-needed-only ICS-formoterol (Steps 1-2) or MART 
(Steps 3-5), beware of risks to the patient if their ICS-formoterol is switched without 
consultation (e.g., in health systems where medication substitution by pharmacists or nurses is 
permitted) to a combination non-formoterol ICS-LABA, as these are not suitable for as-
needed use. 
Stepping down to find the minimum effective dose: When good asthma control has been 
achieved and maintained for 2-3 months, consider stepping down to find the lowest effective 
step. Do not completely withdraw ICS, except if needed temporarily while confirming the 
diagnosis of asthma. Adults and adolescents with well-controlled asthma while on daily low-
dose controller therapy can step down to either as-needed ICS-formoterol16, 21, 33 or to as-
needed ICS+SABA taken together42, 43 (GINA 2021, Box 3-7). 
Stepping up if asthma remains uncontrolled: Before considering any sustained step up, 
first check inhaler technique, adherence, persistent allergen exposure and comorbidities. 
There is no evidence to support specific recommendations about when to increase from as-
needed-only ICS-formoterol in Steps 1-2 to Step 3 MART by adding maintenance ICS-
formoterol, but it should be prompted by factors such as ongoing use of as-needed ICS-
formoterol on most days/week or further exacerbations. 
Patients with risk factors for exacerbations: Prescribe an ICS-containing controller, 
preferably with ICS-formoterol as reliever, as this reduces the risk of severe exacerbations15, 
16, 21, 24, 25, 33, 46. Arrange review more frequently than for patients at low risk. Identify and 
address modifiable risk factors, e.g., smoking, over-use of SABA, comorbidities (GINA 2021, 
Box 3-8). Consider non-pharmacological strategies, such as smoking cessation advice and 
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trigger avoidance, to improve symptom control and/or reduce risk (GINA 2021, Box 3-9). 
Management of exercise-induced symptoms: For patients with dyspnea or wheezing on 
exertion, distinguish between exercise-induced bronchoconstriction and symptoms due to 
obesity, poor cardiopulmonary fitness, or alternative diagnoses such as inducible laryngeal 
obstruction. For patients with exercise-induced bronchoconstriction, prescribe ICS-containing 
controller treatment and advise sufficient warm-up before exercise.26 Patients using as-needed 
ICS-formoterol as their reliever (Track 1) can use the same medication before exercise, if 
needed, and do not need a SABA inhaler.27 
Rationale: For pre-exercise use by adults and adolescents, formoterol was recommended in 
guidelines for many years as an effective and safe alternative to albuterol,26 but is no longer 
promoted because of risks of LABA-only treatment. Pre-exercise ICS-formoterol avoids this 
risk and is as effective as daily ICS plus pre-exercise SABA in reducing exercise-induced 
bronchoconstriction.27 
GINA steps for children aged 6-11 
Treatment steps for children are shown in Figure 4. In Step 1, for children with initial 
symptoms <twice/month, taking ICS whenever SABA is taken for symptom relief is preferred 
over regular ICS or as-needed SABA alone. Regular low-dose ICS with as-needed SABA is 
recommended in Step 2 for most children with asthma, but attention must be paid to 
adherence.  
In Step 3, options include low-dose ICS-LABA, medium-dose ICS or very low-dose 
budesonide-formoterol MART.52 In Step 4, options include medium-dose ICS-LABA53 or 
low-dose MART (Table 1, Table E2 and downloadable resource). For all children at Step 4, 
consider referral for expert advice. In children, before stepping up, consider trying other 
controller options at the same step. 
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Rationale: The addition of as-needed concomitant ICS+SABA as anti-inflammatory reliever 
in Step 1 for children was based on evidence from two studies in which children and 
adolescents were stepped down from regular ICS to as-needed ICS plus SABA in separate 
inhalers,44, 45 and because of likely nonadherence with daily ICS by children with infrequent 
symptoms. For Step 2, there is much more evidence for safety and effectiveness of low-dose 
ICS, but in the real world, ICS adherence is extremely low. In Step 3, maintenance and 
reliever therapy (MART) with very low-dose ICS-formoterol52 was previously recommended 
in the GINA report text, and for consistency is now also included in the figure. For Step 4, 
doubling the MART maintenance dose to 100/6 mcg (delivered dose 80/4.5 mcg) 1 inhalation 
twice daily (still ‘low dose’) was included by consensus, given the variation in ICS 
responsiveness between patients (Table 1, Table E2 and downloadable resource). 
Managing asthma with comorbidities and in specific populations 
Identify and manage comorbidities such as rhinosinusitis, obesity and gastro-esophageal 
reflux disease. Multimorbidity contributes to respiratory symptoms and impaired quality of 
life, and some comorbidities contribute to poor symptom control or exacerbations. 
Despite general concerns about medication use in pregnancy, the advantages of actively 
treating asthma in pregnancy to avoid exacerbations markedly outweigh any potential adverse 
effects of usual controller and reliever medications.54 
For details of multi-disciplinary assessment and management of asthma with comorbidities 
and in specific settings, see GINA 2021, Chapter 3D. 
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Diagnosis and initial treatment of patients with features of both asthma and 
COPD 
Asthma and chronic obstructive pulmonary disease (COPD) are umbrella labels for 
overlapping heterogeneous conditions. Symptoms may be similar, and the diagnostic criteria 
overlap. Some patients have features of both asthma and COPD (‘asthma+COPD’), 
particularly smokers and older adults. This is not a single disease entity. It includes several 
clinical phenotypes that are likely caused by a range of underlying mechanisms. 
There are important differences in evidence-based treatment recommendations for asthma4 
versus COPD,55 with treatment with long-acting bronchodilators alone (i.e., without ICS) 
recommended as initial treatment in COPD, but contraindicated in asthma due to the risk of 
severe exacerbations and death. Until more discriminatory risk factors are identified, all 
patients with diagnoses of both asthma and COPD should receive ICS. COPD should be 
managed according to Global Initiative for Chronic Obstructive Lung Disease (GOLD)55 
recommendations. For all patients, provide education on inhaler technique and adherence, and 
advice about smoking cessation, immunizations, physical activity, and management of 
comorbidities. Refer for specialist investigations and multi-disciplinary care, where possible. 
Rationale: The descriptive term ‘asthma+COPD’ is preferred because ‘asthma-COPD 
overlap’ (ACO) was often assumed to represent a single disease. Patients with asthma+COPD 
have a greater burden of symptoms, exacerbations, impaired quality of life, more rapid 
decline in lung function, need for healthcare utilization and higher mortality compared with 
patients with asthma or COPD alone.4 The recommendation for ICS is because several studies 
have shown that patients with diagnoses of both asthma and COPD are at increased risk of 
hospitalization or death if they are treated with LABA compared with ICS-LABA.56-58 
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Difficult-to-treat and severe asthma in adults and adolescents 
Detailed information is provided in the GINA 2021 pocket guide on difficult-to-treat and 
severe asthma (https://ginasthma.org/reports), including an integrated decision tree for 
diagnosis and management across primary and specialist care. A brief summary is included 
below.  
Assessment and optimization of therapy 
Difficult-to-treat asthma is asthma that is uncontrolled despite medium- or high-dose ICS-
LABA treatment, or that requires high-dose ICS-LABA treatment to maintain good symptom 
control and reduce exacerbations. 
Severe asthma is asthma that is uncontrolled despite good adherence with optimized high-
dose ICS-LABA therapy and management of contributory factors, or that worsens when high-
dose treatment is decreased. Approximately 3-10% of people with asthma have severe 
asthma.12, 59 
Assess all patients with difficult-to-treat asthma to confirm the diagnosis of asthma, and to 
identify and manage factors that commonly contribute to symptoms, poor quality of life, 
and/or exacerbations. For patients with persistent symptoms and/or exacerbations despite 
high-dose ICS-LABA, assess the clinical and inflammatory phenotype, as this may guide the 
selection of add-on treatment. Refer for expert advice if asthma does not improve in response 
to optimizing Step 4 or 5 treatment (or earlier, if needed). 
Management of severe asthma 
Refer patients to support services, where available, to help them deal with the heavy physical, 
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emotional, social and financial burden of severe asthma and its treatment.60  
In Step 5, recommended add-on options include LAMA (tiotropium ≥6 years, triple therapy 
with ICS-LABA-LAMA ≥18 years). Adding LAMA provided modest improvement in lung 
function but not symptom control, and exacerbations were reduced in some studies.61-65 Step 4 
MART with ICS-formoterol should be tried before considering add-on LAMA; as-needed 
ICS-formoterol can be continued as the reliever for patients prescribed ICS-formoterol-
LAMA, but for patients prescribed an ICS-LABA-LAMA with non-formoterol LABA, the 
appropriate reliever is SABA. After specialist referral, add-on low-dose azithromycin is 
another option for reducing exacerbations, but risks of antibiotic resistance and prolonged 
QTc interval must be considered.66 Sputum-guided adjustment of ICS dose improves 
outcomes in moderate-to-severe asthma,67 but is not widely available and the optimal 
frequency of sputum assessment is not known. 
With add-on biologic therapies for severe eosinophilic asthma (benralizumab, dupilumab, 
mepolizumab, reslizumab) and severe allergic asthma (dupilumab, omalizumab) the main 
benefits are substantial reduction in severe exacerbation and reduced OCS exposure.68 No 
head-to-head studies are available, but typical eligibility criteria for each class, and predictors 
of good response, are found in the GINA pocket guide decision tree.13 
Maintenance OCS treatment should be avoided, wherever possible, because of its serious 
long-term side-effects.40, 69 
At follow-up, assess the response to any add-on treatment, stop ineffective treatments, and 
consider other options. For patients who respond to add-on therapy, re-evaluate need for other 
therapies every 3-4 months, but do not completely stop ICS. 
Continue to optimize patient care in collaboration with primary care, and consider the 
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patient’s social and emotional needs. Arrange multidisciplinary team care for severe asthma, 
if available. Invite patients with severe asthma to enroll in a registry or clinical trial, if 
available and relevant, to help fill evidence gaps, including comparison of biologic therapy 
options and positioning of bronchial thermoplasty.68 
 
Management of worsening asthma and exacerbations 
Asthma exacerbations represent acute or sub-acute worsening in symptoms and lung function 
from the patient’s usual status. In some cases, a patient may present for the first time during 
an exacerbation. 
For discussion with patients, use terminology that is easily understood; ‘flare-up’ is more 
patient-friendly than the academic term ‘exacerbation’. The terms ‘episodes’, ‘attacks’ and 
‘acute asthma’ are often used, but their meanings vary widely.70 
Preventing severe exacerbations that require treatment with systemic corticosteroids is an 
important goal of asthma management. Even a single OCS course has significant adverse 
effects,39 and taking as few as 4-5 courses of OCS over 7 years’ follow-up is associated with 
increased risk of serious long-term conditions including osteoporosis, pneumonia, 
cardiovascular disease, cataracts, renal impairment, diabetes and weight gain.40, 69 Key 
strategies for reducing exacerbations include ICS-containing treatment (particularly as-
needed-only ICS-formoterol or MART), managing risk factors, and providing a personalized 
written asthma action plan. The reduction in asthma exacerbations seen in many countries 
during the COVID-19 pandemic suggests that public health measures to reduce spread of 
SARS-CoV-2 infections (e.g., handwashing, social/physical distancing, mask-wearing) may 
be important in reducing transmission of other respiratory viruses. 
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Patients at increased risk of asthma-related death should be identified, and reviewed more 
frequently. Factors include a history of requiring intubation and mechanical ventilation, 
hospitalization or emergency department (ED) visit for asthma in the previous year, not 
currently using or poorly adherent with ICS-containing therapy, over-use of SABAs,38 a 
history of psychiatric disease or psychosocial problems, concomitant food allergy, and 
currently using or having recently stopped OCS (a marker of exacerbation severity) (GINA 
2021, Box 4-1). 
Written asthma action plans 
As part of asthma self-management, provide all patients with a written asthma action plan 
appropriate for their level of asthma control and health literacy, so they know how to 
recognize and respond to worsening asthma.19 State when and how to change reliever and 
controller medications, use OCS if appropriate, and access medical care if symptoms fail to 
respond to treatment. Base the action plan on changes in symptoms or (only in adults) PEF.19 
Advise patients who have a history of rapid deterioration to go to an acute care facility or see 
their doctor immediately if their asthma starts to worsen. 
Action plan recommendations for responding to worsening asthma depend on the patient’s 
usual therapy. Patients prescribed as-needed ICS-formoterol alone or in MART increase their 
as-needed doses as symptoms increase. Those on maintenance ICS-containing controller 
should increase to high dose temporarily (e.g., for 1-2 weeks) (see GINA 2021, Box 4-2). 
Rationale: In a systematic review of self-management studies, action plans in which the ICS 
dose was at least doubled were associated with improved asthma outcomes and reduced 
healthcare utilization.71 In some studies in adults and adolescents19, 72 and pre-school 
children,73 short-term higher-dose ICS reduced progression to a severe exacerbation and some 
Page 28 of 75
 AJRCCM Articles in Press. Published as 10.1164/rccm.202109-2205PP 
 Copyright © by the American Thoracic Society 
GINA 2021 Executive summary  
27 
found less impact on serum cortisol than OCS,74, 75 but cost may be an issue. Given the shape 
of the ICS dose-response curve, the benefit of increasing maintenance ICS when asthma 
worsens may be greater when background adherence is lower. The timing of an increased ICS 
dose may be important: studies in adults in which the ICS dose was doubled 5-7 days after 
symptoms worsened found no reduction in severe exacerbations.76, 77 In contrast, in 
maintenance and reliever therapy (MART), taking reliever doses of ICS-formoterol as soon as 
asthma symptoms occur, reduces the risk of progression to severe exacerbation.24, 25  
Management of exacerbations in a primary care or acute care facility 
Assess exacerbation severity from mental state, degree of dyspnea, vital signs, oxygen 
saturation and lung function (PEF or spirometry), while starting treatment with repeated 
administration of SABA (in most patients, by pressurized metered dose inhaler and spacer) 
and controlled flow oxygen (sufficient flow to maintain oxygen saturation at 93-95% for 
adults; 94-98% for children 6-11 years), if available (Figure 5). Controlled oxygen therapy is 
associated with lower mortality and better outcomes than high concentration (100%) oxygen 
therapy.78-80 
Arrange immediate transfer to an acute care facility if there are signs of severe exacerbation, 
or to intensive care, particularly if the patient is drowsy, confused, or has a silent chest. 
During transfer, give inhaled SABA and ipratropium bromide, controlled oxygen and 
systemic corticosteroids. 
Repeated administration of albuterol (up to 4-10 puffs every 20 minutes for the first hour) is 
effective for rapidly reversing airflow limitation81. Avoid nebulization except for life-
threatening asthma; delivery of rapid-acting beta2-agonist via a pressurized metered-dose 
inhaler and spacer or via a dry-powder inhaler is as effective in patients with moderately 
severe acute asthma,81, 82 and avoids risk of disseminating infectious particles. Current 
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evidence does not support the routine use of intravenous beta2-agonists in patients with severe 
asthma exacerbations.83 
Start OCS early after presentation. For adults, give prednisolone 40-50 mg/day (or equivalent) 
for 5-7 days. For children, give prednisolone 1-2 mg/kg (maximum 40 mg) for 3-5 days. 
Tapering is not needed if administered for <2 weeks. 
Review response of symptoms, vital signs, oxygen saturation and lung function after 1 hour 
(or earlier if worsening). Give ipratropium bromide only for severe exacerbations. Consider 
intravenous magnesium sulfate for patients with severe exacerbations not responding to initial 
treatment.  
Do not routinely request a chest radiography or routinely prescribe antibiotics for asthma 
exacerbations.  
The decision whether to hospitalize should be based on the patient’s clinical status, lung 
function, response to treatment, recent and past history of exacerbations, social support, and 
ability to manage at home. 
Rationale: Currently, inhaled albuterol is the usual bronchodilator in acute asthma 
management. Similar efficacy and safety of formoterol in ED have been reported.84 In one 
study, high-dose budesonide-formoterol had similar efficacy and safety to SABA in ED 
patients.85 
Discharge management 
Before the patient goes home, arrange ongoing treatment. This should include starting ICS-
containing controller treatment, preferably ICS-formoterol as MART (Table 1, Table E2, 
downloadable resource) to reduce the risk of another exacerbation, or stepping up the dose of 
existing maintenance treatment for 2-4 weeks. Advise patients to use reliever medication as 
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needed, not regularly. Patients prescribed ICS-formoterol as their reliever should return to this 
after an ED presentation. 
Follow-up 
Arrange early follow-up after any exacerbation, regardless of where it was managed: 
• Review the patient’s symptom control and risk factors for further exacerbations.  
• Prescribe/continue ICS-containing controller therapy (preferably MART with ICS-
formoterol) to reduce the risk of further exacerbations. If already taking controller 
therapy, continue increased doses for 2-4 weeks. 
• Provide a written asthma action plan and, where relevant, advice about avoiding 
exacerbation triggers. 
• Check inhaler technique and adherence.  
Asthma outcomes after an ED presentation for acute asthma are significantly improved by 
comprehensive intervention programs that include optimal controller management, inhaler 
technique, and elements of self-management education (self-monitoring, written action plan 
and regular review).86, 87 
Referral for expert advice should be considered for patients who have been hospitalized for 
asthma, or who have repeat presentations to acute care settings. Follow-up by a specialist is 
associated with fewer subsequent ED visits or hospitalizations and better asthma control.87 
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Diagnosis and management of asthma in children 5 years and younger 
Diagnosis 
Recurrent wheezing occurs in a large proportion of children 5 years and younger, typically 
with viral respiratory infections. Recognizing when this is the initial presentation of asthma is 
difficult. In young children with a history of wheezing, a diagnosis of asthma is more likely if 
they have any of the following: 
• wheezing or coughing that occurs with exercise, laughing or crying, particularly in the 
absence of an apparent respiratory infection 
• allergic sensitization, eczema, allergic rhinitis or food allergy, or asthma in first-
degree relatives 
• clinical improvement during 2-3 months of controller treatment, and worsening after 
cessation. 
It is particularly important in this age group to consider and exclude alternative causes of 
wheeze, cough and breathlessness (GINA 2021, Box 6-3). 
Important indications for referral of children ≤5 years for further diagnostic investigations 
include neonatal/very early onset of symptoms, failure to thrive, continuous wheezing, 
symptoms not associated with typical triggers (e.g., viral respiratory infections), or associated 
with vomiting, focal lung or cardiovascular signs, finger clubbing, hypoxemia outside the 
context of viral illness, or failure to respond to asthma medications. 
Initial treatment 
The goals of asthma management in young children are to achieve good control of symptoms 
and maintain normal activity levels, and to minimize the risk of asthma exacerbations, 
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impaired lung development and medication side-effects. 
Wheezing episodes in young children should be treated initially with inhaled SABA, 
regardless of whether the diagnosis of asthma has been made. However, SABAs are generally 
ineffective for initial episodes of wheeze in children younger than 1 year with infectious 
bronchiolitis. 
A trial of controller therapy (e.g., for 3 months) should be given if the symptom pattern 
suggests asthma, alternative diagnoses have been excluded, and respiratory symptoms are 
uncontrolled and/or wheezing episodes are frequent or severe (Figure 6). Response to 
treatment should be reviewed before deciding whether to continue it. If the response is absent 
or incomplete, reconsider alternative diagnoses. 
It is important to discuss controller treatment choices with the child’s parent/caregiver, to 
explain the relative benefits and risks of treatment, and the importance of maintaining normal 
activity levels for their child’s physical and social development. 
The choice of inhaler device should be based on the child’s age and capability. The preferred 
device is a pressurized metered dose inhaler and spacer, with face mask for children younger 
3 years, and mouthpiece for most aged 3-5 years. Children should be switched from a face 
mask to mouthpiece as soon as they can demonstrate good technique.   
Review the need for asthma treatment frequently, as asthma-like symptoms remit in many 
young children or may be markedly seasonal. Measure the child’s height at least once every 
year. 
Asthma treatment steps for children ≤5 years 
Step 1: Provide inhaled SABA for relief of wheezing episodes. Need for SABA more than 
twice a week on average over 1 month indicates the need for a trial of controller medication. 
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Step 2: The preferred option is regular daily low-dose ICS plus as-needed SABA, given for at 
least 3 months (see GINA 2021, Box 6-6 for ICS doses). Regular montelukast is less effective 
than low-dose ICS, and parents/caregivers should be counselled about potential 
neurobehavioral adverse effects, as in a boxed warning from the US Food and Drug 
Administration.88 
Step 3: Before considering step-up to double the ‘low’ ICS dose, check for concomitant or 
alternative diagnoses, check and correct inhaler technique and adherence, and ask about risk 
factors such as exposure to allergen or tobacco smoke. ICS-LABA is not recommended in 
children <4 years old, as there are insufficient data about efficacy and safety.  
Step 4: Refer the child for expert advice if symptoms and/or flare-ups persist, or at any time if 
side-effects of treatment are observed or suspected, or if there are doubts about diagnosis. See 
GINA 2021 Chapter 6 for details about other therapeutic options. 
Managing exacerbations 
Early symptoms of exacerbations in young children may include increased symptoms, 
increased coughing (especially at night), lethargy or reduced exercise tolerance, impaired 
daily activities including feeding, and a poor response to reliever medication.  
Managing exacerbations at home: Give a written asthma action plan to parents/caregivers 
of young children with asthma so they can recognize an impending exacerbation, start 
treatment, and identify when urgent hospital treatment is required. Initial treatment at home is 
with inhaled SABA, with review after 1 hour or earlier. If inhaled SABA is needed more 
often than 3-hourly or for >24 hours, treatment by a health provider is needed on the same 
day. Parents/caregivers should seek urgent medical care if the child is acutely distressed, 
lethargic, fails to respond to initial bronchodilator therapy, or is worsening, especially in 
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children younger than 1 year. 
Rationale: Most children with wheezing due to asthma respond to SABA. There is 
insufficient evidence for parent-initiated OCS in this age-group. Preemptive episodic parent-
initiated high-dose nebulized ICS may reduce exacerbations in children with intermittent 
viral-triggered wheezing89 but there are no long-term studies and a high risk of side-effects; it 
should only be considered if the clinician is confident that it will be used appropriately, and 
the child monitored closely for side-effects. 
Managing exacerbations in primary care or acute care facility: Assess severity of the 
exacerbation while initiating treatment with SABA (2-6 puffs every 20 minutes for first hour) 
and controlled oxygen to maintain saturation 94-98%. Arrange immediate transfer to hospital 
if the child shows no response to inhaled SABA within 1-2 hours,  is unable to speak or drink, 
has a respiratory rate >40/minute or is cyanosed, has oxygen saturation <92% on room air, or 
cannot be safely cared for at home.  
For children attending an ED or admitted to hospital with asthma, consider systemic 
corticosteroids: oral prednisone/prednisolone 1-2 mg/kg/day for up to 5 days (maximum of 
20 mg/day for children 0-2 years and 30 mg/day for children 3-5 years) or dexamethasone 
0.6 mg/kg/day for 2 days. 
Follow-up: Children who have experienced an asthma exacerbation are at risk of further 
exacerbations. Arrange follow-up within 1-2 days of an exacerbation and again 1-2 months 
later to identify modifiable risk factors and exacerbation triggers, optimize ongoing asthma 
management, and check inhaler technique and adherence. 
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Primary prevention of asthma in children 
The development and persistence of asthma are driven by gene-environment interactions. For 
children, a ‘window of opportunity’ to prevent asthma exists in utero and in early life, but 
intervention studies are limited. Current advice and recommendations for preventing asthma 
in children, based on high-quality evidence90, 91 or consensus, include the following: 
• Avoid exposure to environmental tobacco smoke during pregnancy and after birth. 
• Encourage vaginal delivery where possible. 
• Where possible, avoid the use of acetaminophen and broad-spectrum antibiotics 
during the first year of life. 
• Identification and correction of Vitamin D insufficiency in women with asthma who 
are pregnant, or planning pregnancy, may reduce the risk of early life wheezing 
episodes, but not asthma. 
• Allergen avoidance strategies directed at a single allergen have not been effective in 
preventing asthma. Multifaceted strategies may be effective, but the essential 
components have not been identified. 
Breast-feeding is advised for its general health benefits. 
 
Implementation of asthma management strategies into health systems 
To improve asthma care and patient outcomes, evidence-based recommendations must be 
disseminated and implemented nationally and locally, and integrated into health systems and 
clinical practice.92 Implementation requires an evidence-based strategy involving professional 
groups and stakeholders and considering local cultural and socioeconomic conditions. Cost-
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effectiveness of implementation programs should be assessed so a decision can be made to 
pursue or modify them. Local adaptation and implementation of asthma care strategies are 
aided by purpose-developed tools.92 
 
Asthma management in low-resource settings 
GINA 2021 is a global strategy relevant to the care of all children, adolescents and adults with 
asthma, wherever they live. Most of the global burden of asthma morbidity and mortality 
occurs in low-income and middle-income countries,1, 93 due to lack of necessary resources for 
effective long-term asthma care.1, 93, 94 GINA has identified ongoing lack of access to ICS as a 
serious concern4, especially as they can be produced at low cost. The safest and most effective 
approach to asthma treatment in adolescents and adults, which also avoids the consequences 
of starting treatment with SABA alone, depends on access to ICS-formoterol across all 
asthma severity levels.4 However, despite listing of budesonide-formoterol on WHO’s 
Essential Medicines List,95 affordable access is very limited in many low-resource settings.1, 4, 
93, 94, 96 The urgent need to ensure access to affordable quality-assured inhaled asthma 
medications as part of universal health coverage must now be prioritized by all relevant 
stakeholders, particularly manufacturers of inhalers on the WHO Essential Medicines List.95 
 
Topics requiring further research 
In addition to ongoing evidence reviews across the whole asthma strategy, GINA plans to 
review the following topics:  
• the definition of mild asthma 
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• assessment of symptom control in patients whose reliever is ICS-formoterol 
• subcutaneous and sublingual allergen immunotherapy 
• the diagnosis and management of asthma in pre-school children 
• the use of digital tools and communication in asthma management 
• management of asthma in low- and middle-income countries. 
GINA also plans to develop a pocket guide for severe asthma in children 6-11 years. COVID-
19 advice on the GINA website will be updated as new evidence emerges. 
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[Figure legends] 
Figure 1. GINA assessment of asthma control in adults, adolescents and children 6–11 
years 
Source: GINA 2021 (Box 2-2)4 
For a fully referenced version of this table, please see GINA strategy report 2021. 
BD: bronchodilator; FEV1: forced expiratory volume in 1 second; FeNO: fractional exhaled 
nitric oxide; ICS: inhaled corticosteroid; OCS: oral corticosteroid; P450 inhibitors: 
cytochrome P450 inhibitors such as ritonavir, ketoconazole, itraconazole; SABA: short-acting 
beta2-agonist. 
*Based on SABA (as-needed ICS-formoterol reliever not included); excludes reliever taken 
before exercise. For children 6-11 years, see also GINA 2021, Box 2-3). For specific risk 
reduction strategies, see GINA 2021, Box 3-8. 
†‘Independent’ risk factors are those that are significant after adjustment for the level of 
symptom control. 
 
Figure 2. Personalized asthma management cycle of care 
Source: GINA 2021 (Box 3-2)4 
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Figure 3. Personalized management for adults and adolescents to control symptoms and 
minimize risk 
Source: GINA 2021 (Box 3-5A)4 
HDM: house dust mite; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; 
LAMA: long-acting muscarinic antagonist; LTRA: leukotriene receptor antagonist; OCS: oral 
corticosteroids; SABA: short-acting beta2-agonist; SLIT: sublingual immunotherapy. For ICS 
doses, see GINA 2021, Box 3-6. 
 
Figure 4. Personalized management for children 6–11 years to control symptoms and 
minimize future risk 
Source: GINA 2021 (Box 3-5B)4 
BUD-FORM: budesonide-formoterol; ICS: inhaled corticosteroid; LABA: long-acting beta2-
agonist; LTRA: leukotriene receptor antagonist; MART: maintenance and reliever therapy 
with ICS-formoterol; OCS: oral corticosteroids; SABA: short-acting beta2-agonist. For ICS 
doses for children, see GINA 2021, Box 3-6. For MART doses, see Table E2 and  
downloadable resource. 
 
Figure 5. Management of asthma exacerbations in primary care (adults, adolescents, 
children 6-11 years) 
Source: GINA 2021 (Box 4-3)4 
O2: oxygen; PEF: peak expiratory flow; SABA: short-acting beta2-agonist (doses are for 
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Figure 6. Personalized management of asthma in children 5 years and younger 
Source: GINA 2021 (Box 6-5)4 
ICS: inhaled corticosteroids; LTRA: leukotriene receptor antagonist; SABA: short-acting 
beta2 agonist
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Table 1. Differences between current asthma treatment regimens containing an anti-
inflammatory reliever (AIR) 
 
Anti-inflammatory reliever (AIR) 
therapy alone (GINA Steps 1–2) 
Maintenance and reliever therapy 
(MART*) (GINA Steps 3, 4, 5) 
Definition Combination ICS-formoterol taken as 
needed for symptom relief†, without 
maintenance therapy 
or, if not available, low-dose ICS 
taken whenever SABA is taken for 
symptom relief 
Daily maintenance ICS-formoterol  
PLUS 
Low-dose ICS-formoterol taken as needed 
for symptom relief† 
Indications Mild asthma: GINA Steps 1–2  Moderate-to-severe asthma: 
GINA Steps 3, 4 and 5 
Explanation  Whenever symptom relief is needed, 
the patient takes an inhaler containing 
a combination of a low dose of ICS 
and formoterol (instead of a SABA), 
without daily maintenance treatment.  
Or, if ICS-formoterol is not available, 
they take a low dose of ICS whenever 
SABA is taken 
The patient takes regular daily 
maintenance controller treatment with 
low-dose (Step 3) or medium dose (Step 4) 
combination ICS-formoterol. 
PLUS  
Whenever needed for symptom relief, the 
patient uses an inhaler containing a 
combination of a low dose of ICS and 
formoterol (instead of a SABA).  
Medications 
and age-
Budesonide-formoterol (≥12 years) 
There have been smaller studies with 
Budesonide-formoterol (ages ≥4 years)  
or beclometasone-formoterol (adults 
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combination or separate inhalers in 
adults ≥18 years, adolescents and 
children ≥4 years. 
≥18 years)  
Rationale In patients with mild asthma, as-
needed-only budesonide-formoterol 
reduced severe exacerbations by 
≥60% compared with SABA alone, 
with similar symptom control and 
lung function as maintenance ICS 
plus as-needed SABA.  
With as-needed-only ICS+SABA in 
patients with mild asthma, some 
studies showed fewer exacerbations 
than SABA alone; other studies 
showed similar outcomes to 
physician-adjusted ICS treatment. 
In moderate-severe asthma, maintenance 
and reliever therapy with ICS-formoterol 
reduced severe exacerbations compared 
with same or high dose ICS or ICS-LABA 
plus as-needed SABA, with similar 
symptom control and lung function.  
There have been no studies with ICS+SABA 
used as both maintenance and reliever 
therapy, and some evidence suggests that 
taking ICS+SABA regularly may increase 
exacerbation risk. 
AIR: anti-inflammatory reliever, a term used for reliever inhalers that contain a combination 
of an ICS with either formoterol or albuterol; ICS: inhaled corticosteroid; LABA: long-acting 
beta2 agonist; MART: maintenance and reliever therapy; SABA: short-acting beta2-agonist 
* Also called single-inhaler maintenance and reliever therapy (SMART) 
† For dosage details, see Table E2 and downloadable resource in the online data supplement 
ICS-formoterol contains a combination of an inhaled corticosteroid (e.g., budesonide or 
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beclometasone) and formoterol, a rapid-onset long-acting beta2-agonist that, for most patients, 
relieves symptoms and bronchoconstriction as quickly as a SABA. When 
budesonide-formoterol or beclometasone-formoterol are used as needed, a single 
inhalation is taken for symptom relief. If symptoms persist after a few minutes, an additional 
inhalation can be taken, but no more than 6 inhalations should be taken on a single occasion 
(4 inhalations of budesonide-formoterol for children 4–11 years). The maximum total dose 
(reliever inhalations plus maintenance inhalations, if used) that can be used temporarily in a 
single day is 12 inhalations of budesonide-formoterol for adults/adolescents (total 8 
inhalations for children 4–11 years) and total 8 inhalations of beclometasone-formoterol for 
adults. If patients need more than this, they should seek medical help the same day.  
Other ICS-formoterol formulations (e.g., mometasone-formoterol, fluticasone propionate-
formoterol) have not been studied as anti-inflammatory relievers, either alone or in MART, 
but could be substituted if budesonide-formoterol or beclometasone-formoterol is not 
available. Before prescribing any inhaler, ensure that the patient can use it correctly.  
The recommended maximum doses refer to the maximum total dose that can be taken 
temporarily on any single day, not the expected or desirable average use. In clinical trials of 
as-needed budesonide-formoterol in adults and adolescents with mild asthma, patients used an 
average of only 3-4 inhalations per week of low-dose budesonide-formoterol, and <0.1% of 
patients took >8 inhalations of budesonide-formoterol on more than 1 day during the 
12 months of treatment.21, 33  
For all patients prescribed as-needed-only ICS-formoterol or MART, average frequency of 
as-needed use of ICS-formoterol over the previous 4 weeks should be reviewed at each visit 
as part of the assessment of their treatment needs, especially when considering the need for 
maintenance treatment. 
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Combinations of ICS with non-formoterol long-acting beta2-agonists (LABA), or 
combinations of ICS, LABA and long-acting muscarinic antagonists (LAMA), should not be 
used as-needed; they are recommended only for maintenance treatment. For patients using a 
non-formoterol ICS-LABA (with or without a LAMA), the appropriate reliever is SABA.
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Figure 2. Personalized asthma management cycle of care 
 
Figure footnotes 
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Table E1. Diagnostic criteria for asthma in adults, adolescents, and children 6–11 years 
 
Source: Box 1-2 in Global Initiative for Asthma. Global Strategy for Asthma Management and 
Prevention, 2021 [cited September 2021]. 2021. Available from: www.ginasthma.org. 
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BD: bronchodilator (SABA or rapid-acting LABA such as ICS-formoterol); FEV1: forced 
expiratory volume in 1 second; ICS: inhaled corticosteroid; LABA: long-acting beta2-agonist; PEF: 
peak expiratory flow (highest of three readings); SABA: short-acting beta2-agonist. 
* If possible, confirm the diagnosis before starting controller treatment. 
† BD responsiveness may be lost after starting ICS treatment, during severe exacerbations or viral 
respiratory infections, of if airflow limitation has become persistent over time. If responsiveness is 
not present at initial presentation, the next step depends on the availability of other tests and the 
urgency of the need for treatment. For patients already on controller treatment, see GINA 2021, Box 
1-3. 
‡ Daily diurnal PEF variability is calculated from twice daily PEF as (day’s highest minus day’s 
lowest) divided by (mean of day’s highest and lowest), averaged over one week. 
§Use the same peak flow meter each time, as PEF may vary by up to 20% between different meters.  
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Table E2. Summary of medications and dosages for asthma treatment regimens containing anti-inflammatory reliever 
 
Anti-inflammatory reliever (AIR) therapy 
alone GINA Steps 1–2 
Maintenance and reliever therapy (MART)  
GINA Steps 3, 4 and 5 
Definition 
Combination ICS-formoterol taken as needed for 
symptom relief†, without maintenance therapy 
or, if not available, low-dose ICS taken whenever 
SABA is taken for symptom relief 
Daily maintenance ICS-formoterol  
PLUS 
Low-dose ICS-formoterol taken as needed for symptom relief† 
Indications Mild asthma: GINA Steps 1–2  Moderate-to-severe asthma: GINA Steps 3, 4 and 5 
Explanation  Whenever symptom relief is needed, the patient takes an inhaler containing a combination of a 
low dose of ICS and formoterol (instead of a 
SABA), without daily maintenance treatment 
or, if ICS-formoterol is not available, they take a 
low dose of ICS whenever SABA is taken 
The patient takes regular daily maintenance controller treatment with low-dose (Step 3) or 
medium dose (Step 4) combination ICS-formoterol 
PLUS  
whenever needed for symptom relief, the patient uses an inhaler containing a combination of 
a low dose of ICS and formoterol (instead of a SABA)  
MEDICATIONS AND SUGGESTED DOSAGES BY AGE-GROUP 
 Anti-inflammatory reliever therapy AIR alone: 
GINA Steps 1–2 
MAINTENANCE AND RELIEVER THERAPY 
(MART): GINA STEP 3 
MAINTENANCE AND RELIEVER 





Budesonide-formoterol 200/6 mcg [160/4.5 
delivered dose), 1 inhalation as needed for 
symptom relief.  
Budesonide-formoterol 200/6 mcg [160/4.5 
delivered dose]: 1 inhalation twice daily (or once 
daily) as maintenance treatment,  
PLUS  
1 inhalation as needed for symptom relief.  
Budesonide-formoterol 200/6 mcg 
[160/4.5 delivered dose]: 2 inhalations 
twice daily as maintenance treatment, 
PLUS 
1 inhalation as needed for symptom relief 
If symptom persist after a few minutes, another inhalation of ICS-formoterol can be taken. No more than 6 inhalations should be taken on a 
single occasion. A maximum total of 12 doses (reliever doses plus maintenance doses, if used) can be taken temporarily in a single day; if more 
is needed, medical attention should be sought the same day. 
Children 4–
11 years 
[ICS-formoterol not studied] Budesonide-formoterol 100/6 mcg [80/4.5 
delivered dose]: 1 inhalation once daily as 
maintenance treatment,  
PLUS  
1 inhalation as needed for symptom relief.  
Suggested dose: budesonide-formoterol 
100/6 mcg [80/4.5 delivered dose]: 
1 inhalation twice daily as maintenance 
treatment,  
PLUS  
1 inhalation as needed for symptom relief.  
If symptom persist after a few minutes, another inhalation can be taken. For children, no more 
than 4 inhalations should be taken on a single occasion. A maximum total of 8 doses (reliever 
doses plus maintenance doses) can be taken temporarily in a single day; if more is needed, 
medical attention should be sought the same day. 
Beclometasone dipropionate-formoterol (BDP-formoterol) 
Beclometasone-
formoterol – 
adults ≥18 years 
(not studied in 
children or 
adolescents) 
[BDP-formoterol not studied] BDP-formoterol 100/6 mcg [87.5/5 mcg 
delivered dose]: 1 inhalation twice daily (or once 
daily) as maintenance treatment,  
PLUS 
1 inhalation as needed for symptom relief.  
If symptoms persist, another inhalation can be 
taken. No more than 6 doses should be taken 
on a single occasion. A maximum total of 8 
doses (reliever doses plus maintenance doses) 
can be taken temporarily in a single day; if more 
is needed, medical attention should be sought 
the same day. 
[BDP-formoterol not studied] 




17 years and 
children 6–11 
years 
Beclometasone 50 mcg and albuterol 100 mcg 
[40 mcg and 90 mcg delivered dose, 
respectively] 2 inhalations of each separate 
inhaler (or 2 inhalations of combination inhaler) 
as needed for symptom relief. Currently there is 
no different recommendation for maximum daily 
use compared with albuterol alone (12 puffs). 
[ICS-SABA not studied] [ICS-SABA not studied] 
 
AIR: anti-inflammatory reliever; BDP: beclometasone dipropionate; ICS: inhaled corticosteroid; MART: maintenance and reliever therapy with ICS-
formoterol (also called SMART); SABA: short-acting beta2-agonist 
ICS-formoterol contains an inhaled corticosteroid (e.g., budesonide or beclometasone) and formoterol, a rapid-onset long-acting beta2-agonist.  
• Budesonide-formoterol is approved for adults and adolescents ≥12 years in many countries for use in as-needed-only ICS-formoterol therapy 
and MART, and in some countries for MART in children 4–11 years. For budesonide-formoterol, the maximum total number of inhalations that 
can be taken temporarily in any single day (reliever plus maintenance inhalations, if used) is based on the total dose of formoterol in any day. 
(72 mcg of formoterol [54 mcg delivered dose] for adults and adolescents, 48 mcg [36 mcg delivered dose] for children 4–11 years) 
Most of the studies with budesonide-formoterol as reliever used a dry powder inhaler, but budesonide-formoterol pressurized metered dose 
inhaler 200/6 mcg [160/4.5 delivered dose] was used in one Step 4 MART study, also with 1 inhalation per as-needed dose (E1). 
• Beclometasone-formoterol is approved for MART in adults 18 years and older in many countries. A maximum total of 8 inhalations (total of 
reliever inhalations and maintenance inhalations) can be taken temporarily in a single day.  
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GINA 2021 Executive summary. Online supplement  
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• Other ICS-formoterol formulations (e.g., mometasone-formoterol, fluticasone-formoterol) have not been studied with either as-needed-only 
anti-inflammatory reliever (AIR) therapy or MART, but may be able to be substituted if budesonide-formoterol or beclometasone-formoterol 
are not available. Some ICS-formoterol devices are currently approved only for adults 18 years and older. 
Before prescribing any inhaler, ensure that the patient can use it correctly.  
The above recommended maximum doses refer to the maximum total dose that can be taken temporarily on any single day. If a patient needs to take 
more, they should seek medical care the same day. In clinical trials of as-needed-only anti-inflammatory reliever therapy in mild asthma, average use 
of as-needed low dose budesonide-formoterol was 3–4 inhalations per week, and <0.1% of patients took >8 inhalations of budesonide-formoterol on 
more than 1 day during the 12-month studies (E2, E3). 
For all patients prescribed as-needed only Anti-Inflammatory Reliever (AIR) therapy alone or Maintenance And Reliever Therapy (MART), the 
average frequency of as-needed use of ICS-formoterol in the previous 4 weeks should be reviewed at each visit as part of the assessment of their 
treatment needs.  
Combinations of ICS with non-formoterol long-acting beta2-agonists (LABA), or combinations of ICS, LABA and long-acting muscarinic antagonists 
(LAMA), should not be used as-needed. These medications are recommended only for maintenance treatment. For patients prescribed ICS-LABA-
LAMA with a non-formoterol LABA, the reliever should be SABA. 
 




E1.  Patel M, Pilcher J, Pritchard A, Perrin K, Travers J, Shaw D, Holt S, Harwood M, Black P, Weatherall M, Beasley R, The SMART Study Group. 
Efficacy and safety of maintenance and reliever combination budesonide–formoterol in patients with asthma at risk of severe exacerbations: a 
randomised controlled trial. Lancet Respir Med 2013; 1: 32-42. 
E2. O'Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled combined 
budesonide–formoterol as needed in mild asthma. N Engl J Med 2018; 378: 1865-1876. 
E3. Bateman ED, Reddel HK, O'Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-needed 
budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 2018; 378: 1877-1887. 
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Click here for downloadable resource: GINA 2021 Summary of medications and dosages for 
asthma treatment regimens containing an anti-inflammatory reliever 
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GINA 2021
Summary of medications and dosages 
for asthma treatment regimens containing  
an anti-inflammatory reliever
Copyright © 2021 · All Rights Reserved · Global Initiative for Asthma – GINA
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ANTI-INFLAMMATORY RELIEVER (AIR) 
THERAPY ALONE: GINA STEPS 1–2
MAINTENANCE AND RELIEVER THERAPY 
(MART): GINA STEP 3
MAINTENANCE AND RELIEVER THERAPY 
(MART): GINA STEPS 4–5
BUDESONIDE-FORMOTEROL 200/6 mcg, 
1 inhalation as needed for symptom relief.
BUDESONIDE-FORMOTEROL 200/6 mcg: 1 inhalation 
twice daily (or once daily) as maintenance treatment, 
PLUS 1 inhalation as needed for symptom relief. 
BUDESONIDE-FORMOTEROL 200/6 mcg: 2 inhalations 
twice daily as maintenance treatment, PLUS 1 inhalation 
as needed for symptom relief
[Beclometasone dipropionate (BDP)-formoterol 
not studied]
BDP-FORMOTEROL 100/6 mcg: 1 inhalation twice  
daily (or once daily) as maintenance treatment, PLUS  
1 inhalation as needed for symptom relief. Studied only  
in adults.
[BDP-formoterol not studied]
If symptom persist after a few minutes, another inhalation of ICS-formoterol can be taken. No more than 6 inhalations should be  
taken on a single occasion. A maximum total of 12 doses (reliever doses plus maintenance doses, if used) can be taken temporarily  
in a single day (8 inhalations for BDP-formoterol); if more is needed, medical attention should be sought the same day.
BECLOMETASONE DIPROPIONATE 50mcg AND 
ALBUTEROL 100 mcg: 2 inhalations of each separate 
inhaler (or 2 inhalations of combination inhaler) as 
needed for symptom relief. Currently there is no different 
recommendation for maximum daily use compared with 
albuterol alone (12 puffs).
[ICS-SABA not studied]
MEDICATIONS AND SUGGESTED DOSAGES* – ADULTS AND ADOLESCENTS ≥12 YEARS
Global Initiative for Asthma (GINA)
GINA 2021 - asthma treatment regimens containing an anti-inflammatory reliever
AIR: Anti-Inflammatory Reliever; BDP: beclometasone-dipropionate; ICS: inhaled corticosteroid; MART: Maintenance And Reliever Therapy with ICS-formoterol; SABA: short-acting beta2-agonist.  
*Doses are metered doses. See page 4 for corresponding delivered doses and for more details about medications and dosing. Copyright © 2021 · All Rights Reserved · Global Initiative for Asthma – GINA 2
Figure source: Box 3-5A in GINA 2021 Strategy ReportAdults & adolescents 
12+ years
Personalized asthma management 
Assess, Adjust, Review  






Confirmation of diagnosis if necessary
Symptom control & modifiable risk factors (including lung function)
Comorbidities
Inhaler technique & adherence
Patient preferences and goals
Treatment of modifiable risk factors and comorbidities
Non-pharmacological strategies
Asthma medications (adjust down/up/between tracks) 









(Track 1). Using ICS-formoterol 
as reliever reduces the risk of 
exacerbations compared with  
using a SABA reliever
CONTROLLER and 
ALTERNATIVE RELIEVER
(Track 2). Before considering 
a regimen with SABA reliever, 
check if the patient is likely to be 
adherent with daily controller RELIEVER: As-needed short-acting β2-agonist
RELIEVER: As-needed low-dose ICS-formoterol
STEPS 1 – 2
As-needed low dose ICS-formoterol
STEP 3
Low dose maintenance  
ICS-formoterol
STEP 4




Refer for phenotypic assessment  
± anti-IgE, anti-IL5/5R, anti-IL4R
Consider high dose ICS-formoterol
Other controller options for 
either track
Low dose ICS whenever SABA taken, 
or daily LTRA, or add HDM SLIT
Medium dose ICS, or add LTRA, 
or add HDM SLIT
Add LAMA or LTRA or HDM SLIT, 
or switch to high dose ICS
Add azithromycin (adults) or LTRA; add 
low dose OCS but consider side-effects
STEP 1
Take ICS whenever SABA taken
STEP 2
Low dose maintenance ICS
STEP 3







Refer for phenotypic assessment 
± anti-IgE, anti-IL5/5R, anti-IL4R 
Consider high dose ICS-LABA
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MEDICATIONS AND SUGGESTED DOSAGES* – CHILDREN 4 –11 YEARS
ANTI-INFLAMMATORY RELIEVER (AIR)  
THERAPY ALONE: GINA STEPS 1–2
MAINTENANCE AND RELIEVER THERAPY 
(MART): GINA STEP 3
MAINTENANCE AND RELIEVER THERAPY 
(MART): GINA STEP 4
[As-needed-only ICS-formoterol not studied in children]
BUDESONIDE-FORMOTEROL 100/6 mcg: 1 inhalation 
once daily as maintenance treatment, PLUS 1 inhalation 
as needed for symptom relief. 
Suggested dose: BUDESONIDE-FORMOTEROL 100/6 mcg: 
1 inhalation twice daily as maintenance treatment, PLUS  
1 inhalation as needed for symptom relief. 
If symptom persist after a few minutes, another inhalation can be taken. For children, no more than 4 inhalations 
should be taken on a single occasion. A maximum total of 8 doses (reliever doses plus maintenance doses)  
can be taken temporarily in a single day; if more is needed, medical attention should be sought the same day.
BECLOMETASONE DIPROPIONATE 50 mcg AND 
ALBUTEROL 100 mcg: 2 inhalations of each separate 
inhaler (or 2 inhalations of combination inhaler) as 
needed for symptom relief. Currently there is no different 
recommendation for maximum daily use compared with 
albuterol alone.
[ICS-SABA not studied]
Global Initiative for Asthma (GINA)




to prevent exacerbations 
and control symptoms
Other controller options 
RELIEVER 
STEP 1
Low dose ICS taken 
whenever SABA taken
Consider daily  
low dose ICS
Children 6-11 years
Personalized asthma management: 
Assess, Adjust, Review
Asthma medication options:  
Adjust treatment up and down for  
individual child’s needs
STEP 2
Daily low dose inhaled corticosteroid (ICS) (see table of ICS 
dose ranges for children)
Daily leukotriene receptor antagonist (LTRA), or
low dose ICS taken whenever SABA taken
STEP 3
Low dose ICS-LABA, 
OR medium dose ICS, 










Refer for expert advice
STEP 5
Refer for phenotypic 
assessment ± 




Add-on anti-IL5, or 
add-on low dose 
OCS, but consider 
side-effects
Add tiotropium or 
add LTRA
Low dose  
ICS + LTRA





Child and parent satisfaction
Confirmation of diagnosis if necessary
Symptom control & modifiable risk factors (including lung function)
Comorbidities
Inhaler technique & adherence
Child and parent preferences and goals
Treatment of modifiable risk factors & comorbidities
Non-pharmacological strategies
Asthma medications (adjust down or up)







Figure source: Box 3-5B in GINA 2021 Strategy Report
AIR: Anti-Inflammatory Reliever; BDP: beclometasone-dipropionate; ICS: inhaled corticosteroid; MART: Maintenance And Reliever Therapy with ICS-formoterol; SABA: short-acting beta2-agonist.  
*Doses are metered doses. See page 4 for corresponding delivered doses and for more details about medications and dosing. Copyright © 2021 · All Rights Reserved · Global Initiative for Asthma – GINA
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• Budesonide formoterol is approved for adults and adolescents 12 years and older in many 
countries for use in AIR and MART, and in some countries for MART in children 4–11 years. For 
budesonide-formoterol, the maximum total number of inhalations that can be taken temporarily 
in any single day (reliever plus maintenance inhalations, if used) is based on the total dose of 
formoterol in any day (72mcg of formoterol [54 mcg delivered dose] for adults and adolescents, 
48 mcg [36 mcg delivered dose] for children 4–11 years). Most of the studies with budesonide-
formoterol as reliever used a dry powder inhaler, but budesonide-formoterol pressurized metered 
dose inhaler 200/6 mcg [160/4.5 delivered dose] was used in one Step 4 MART study, also with  
1 inhalation per as-needed dose [Patel et al, Lancet Respir Med 2013; 1: 32-42]. 
• Beclometasone-formoterol is approved for MART in adults 18 years and older in many 
countries. A maximum total of 8 inhalations (total of reliever inhalations and maintenance 
inhalations) can be taken temporarily in a single day. 
• Other ICS-formoterol formulations (e.g. mometasone-formoterol, fluticasone-formoterol) have 
not been studied with either AIR or MART, but may be able to be substituted if budesonide-
formoterol or beclometasone-formoterol are not available. Some ICS-formoterol devices are 
currently approved only for adults 18+ years. 
Before prescribing any inhaler, ensure that the patient can use it correctly. 
The above recommended maximum doses refer to the maximum total dose that can be taken on 
any single day. In clinical trials in mild asthma, average use of as-needed low dose budesonide-
formoterol was 3–4 inhalations per week, and <0.1% of patients took >8 inhalations of 
budesonide-formoterol on more than 1 day during the 12-month studies. 
For all patients prescribed Anti-Inflammatory Reliever (AIR) therapy alone or Maintenance And 
Reliever Therapy (MART), average frequency of as-needed use of ICS-formoterol should be reviewed 
at each visit as part of the assessment of their treatment needs. 
ICS-LABA combinations and ICS-LABA-LAMA combinations that contain a non-formoterol 
LABA should not be used as-needed. These medications are recommended only for 
maintenance treatment.
The tables displayed are intended to summarize medication classes and dosages that have been studied with AIR and MART therapy (by GINA step). It is not an exhaustive list of all possible medications, and readers are asked to investigate locally available 
medications as well as local regulatory constraints. Medication names and formulations vary greatly country to country, and this table is intended to serve as framework for clinical decision support rather than exact, specific prescribing guidance.
Copyright © 2021 · All Rights Reserved · Global Initiative for Asthma – GINA
METERED DOSES AND DELIVERED DOSES FOR MEDICATIONS LISTED IN THIS RESOURCE







Beclometasone-formoterol 100/6 mcg 87.5/5 mcg
Separate inhalers
Beclometasone dipropionate 50 mcg 40 mcg
Albuterol (salbutamol) 100 mcg 90 mcg
4
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